Skip to main content
PMC home page
Heart logoLink to Heart
. 1996 Jun;75(6):576–581.

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

N C Davidson 1, W J Coutie 1, D J Webb 1, A D Struthers 1
PMCID: PMC484380  PMID: 8697160

Abstract

OBJECTIVE: To assess the differential effects of low dose (5 mg) and high dose (20 mg) lisinopril treatment on cardiovascular hormones, renal function, and blood pressure over 24 hours in patients with heart failure. DESIGN: Double-blind crossover study. SETTING: Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee. PATIENTS: 19 patients with chronic heart failure and left ventricular ejection fraction < or = 45%. RESULTS: Plasma concentrations of aldosterone and endothelin were lower on the 20 mg dose (plasma aldosterone mean at peak drug effect: 90.7 v 152.0 pg/ml, P < 0.001; mean at trough effect: 124.7 v 174.4 pg/ml, P < 0.01; plasma endothelin at trough effect 4.70 v 6.04 pmol/l, P = 0.03). Creatinine clearance was lower on 20 mg lisinopril (68.7 v 82.1 ml/min, P < 0.05). The area under the curve for diastolic blood pressure over 24 hours was significantly lower on 20 mg (mean difference 3.0 mm Hg, P = 0.04); for systolic blood pressure there was a similar trend (mean difference 5.7 mmHg, P = 0.05). Plasma concentrations of atrial natriuretic peptide (ANP) and B-type natriuretic peptide were similar for both doses; urinary excretion of ANP was lower on 20 mg (12.2 v 13.6 pmol, P < 0.05). CONCLUSIONS: These results indicate that within the usual therapeutic range, high doses of lisinopril cause greater suppression of selected cardiovascular hormones than low doses in heart failure, but are associated with lower creatinine clearance in some patients.

Full text

PDF
577

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benjamin N., Cockcroft J. R., Collier J. G., Dollery C. T., Ritter J. M., Webb D. J. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989 May;412:543–555. doi: 10.1113/jphysiol.1989.sp017630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berglund H., Nyquist O., Beermann B., Jensen-Urstad M., Theodorsson E. Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure. Br Heart J. 1994 Dec;72(6):521–527. doi: 10.1136/hrt.72.6.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boulanger C., Lüscher T. F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990 Feb;85(2):587–590. doi: 10.1172/JCI114477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. COCATS Guidelines. Guidelines for Training in Adult Cardiovascular Medicine, Core Cardiology Training Symposium. June 27-28, 1994. American College of Cardiology. J Am Coll Cardiol. 1995 Jan;25(1):1–34. [PubMed] [Google Scholar]
  5. Emori T., Hirata Y., Ohta K., Shichiri M., Marumo F. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem Biophys Res Commun. 1989 Apr 14;160(1):93–100. doi: 10.1016/0006-291x(89)91625-2. [DOI] [PubMed] [Google Scholar]
  6. GRIZZLE J. E. THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. Biometrics. 1965 Jun;21:467–480. [PubMed] [Google Scholar]
  7. Hall C., Rouleau J. L., Moyè L., de Champlain J., Bichet D., Klein M., Sussex B., Packer M., Rouleau J., Arnold M. O. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994 May;89(5):1934–1942. doi: 10.1161/01.cir.89.5.1934. [DOI] [PubMed] [Google Scholar]
  8. Haynes W. G., Hand M. F., Johnstone H. A., Padfield P. L., Webb D. J. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest. 1994 Oct;94(4):1359–1364. doi: 10.1172/JCI117470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Holmquist B., Bünning P., Riordan J. F. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem. 1979 Jun;95(2):540–548. doi: 10.1016/0003-2697(79)90769-3. [DOI] [PubMed] [Google Scholar]
  10. Leier C. V., Dei Cas L., Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. 1994 Sep;128(3):564–574. doi: 10.1016/0002-8703(94)90633-5. [DOI] [PubMed] [Google Scholar]
  11. Lenfant C. NHLBI funding policies. Enhancing stability, predictability, and cost control. Circulation. 1994 Jul;90(1):1–1. doi: 10.1161/01.cir.90.1.1. [DOI] [PubMed] [Google Scholar]
  12. McMurray J. J., Ray S. G., Abdullah I., Dargie H. J., Morton J. J. Plasma endothelin in chronic heart failure. Circulation. 1992 Apr;85(4):1374–1379. doi: 10.1161/01.cir.85.4.1374. [DOI] [PubMed] [Google Scholar]
  13. Pacher R., Bergler-Klein J., Globits S., Teufelsbauer H., Schuller M., Krauter A., Ogris E., Rödler S., Wutte M., Hartter E. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993 Jun 1;71(15):1293–1299. doi: 10.1016/0002-9149(93)90543-l. [DOI] [PubMed] [Google Scholar]
  14. Rigat B., Hubert C., Corvol P., Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 1992 Mar 25;20(6):1433–1433. doi: 10.1093/nar/20.6.1433-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Townend J., Doran J., Jones S., Davies M. Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure. Int J Cardiol. 1994 Mar 1;43(3):299–304. doi: 10.1016/0167-5273(94)90210-0. [DOI] [PubMed] [Google Scholar]
  16. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994 Nov;24(5):571–575. doi: 10.1161/01.hyp.24.5.571. [DOI] [PubMed] [Google Scholar]
  17. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., Ogawa H., Okumura K., Mukoyama M., Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994 Jul;90(1):195–203. doi: 10.1161/01.cir.90.1.195. [DOI] [PubMed] [Google Scholar]
  18. Yoshimura M., Yasue H., Tanaka H., Kikuta K., Sumida H., Kato H., Jougasaki M., Nakao K. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J. 1994 Dec;72(6):528–533. doi: 10.1136/hrt.72.6.528. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES